We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

26 hedge funds and large institutions have $14.2M invested in Regulus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,167% more call options, than puts

Call options by funds: $458K | Put options by funds: $3K

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

4% more funds holding

Funds holding: 25 → 26 (+1)

1% less ownership

Funds ownership: 55.97% → 54.97% (-1%)

5% less capital invested

Capital invested by funds: $15M → $14.2M (-$783K)

Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
3
Increased
6
Reduced
4
Closed
2
Calls
$458K
Puts
$3K
Net Calls
+$455K
Net Calls Change
-$80K

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$51.3K
2
Citadel Advisors
Citadel Advisors
Florida
+$22.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$5.99K
4
Citigroup
Citigroup
New York
+$2.83K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.84K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$36K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.75K
3
GC
Grimes & Company
Massachusetts
-$169
4
UBS Group
UBS Group
Switzerland
-$85
5
Osaic Holdings
Osaic Holdings
Arizona
-$68
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$4.96M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$3.74M – – –
NMC
3
NEA Management Company
Maryland
$2.49M – – –
DCM
4
DAFNA Capital Management
California
$1.42M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$367K +$1.84K +1,381 +0.5%
Victory Capital Management
6
Victory Capital Management
Texas
$348K +$51.3K +38,529 +17%
SCM
7
Sarissa Capital Management
Connecticut
$237K – – –
EAM
8
Exome Asset Management
New York
$228K +$238K +178,404 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$157K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$70K +$5.99K +4,500 +9%
State Street
11
State Street
Massachusetts
$53.4K – – –
PCM
12
Prelude Capital Management
New York
$51.5K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$36.4K +$22.3K +16,746 +143%
Northern Trust
14
Northern Trust
Illinois
$23K – – –
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
$22K – – –
GC
16
Grimes & Company
Massachusetts
$13.3K -$169 -127 -1%
Citigroup
17
Citigroup
New York
$2.72K +$2.83K +2,123 New
CB
18
Community Bank
New York
$876 – – –
BlackRock
19
BlackRock
New York
$733 -$60 -45 -7%
UBS Group
20
UBS Group
Switzerland
$440 -$85 -64 -16%
Wells Fargo
21
Wells Fargo
California
$180 +$16 +12 +9%
JP Morgan Chase
22
JP Morgan Chase
New York
$37 +$12 +9 +45%
TRCT
23
Tower Research Capital (TRC)
New York
$22 -$4.75K -3,569 -100%
Bank of America
24
Bank of America
North Carolina
$14 +$15 +11 New
VF
25
Virtu Financial
New York
– -$36K -25,921 Closed
1
2

RGLS Hedge Fund Activity: Q4 2023 in Review

26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2023, worth a combined $14.2M — down 5.2% from $15M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new RGLS positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $51.3K. The largest seller was Virtu Financial, exiting entirely with an estimated $36K sold.

  • 26 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2023, up from 25 in Q3 2023.
  • Funds reported $14.2M of Regulus Therapeutics stock for Q4 2023, down 5.2% quarter-over-quarter.
  • 3 funds opened new Regulus Therapeutics positions in Q4 2023 and 2 closed out, a net change of +1 holder.
  • The largest Regulus Therapeutics buyer in Q4 2023 was Victory Capital Management, an estimated $51.3K added.
  • The largest Regulus Therapeutics seller in Q4 2023 was Virtu Financial, an estimated $36K sold.

Based on aggregated 13F filings for Q4 2023.